Scribe Biosciences was established from technologies developed at the University of California, San Francisco to build droplet microfluidic assays with precise cell ratios.

Scribe's core technology, Microenvironment on Demand (MOD), enables the construction of hundreds of thousands of live cell-based assays (cytotoxicity, secretion) in droplets and selectively profile assay-positive droplets using genomics readouts.

MOD will enable deeper understanding of cancer, heart and autoimmune diseases by linking live-cell assays to genomics at a single-cell resolution.